{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T20:55:10Z","timestamp":1763499310316,"version":"3.45.0"},"reference-count":41,"publisher":"CSIRO Publishing","issue":"2","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":3354,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>INTRODUCTION<\/jats:title>\n                    <jats:p>Treatment of gout, specifically with colchicine, varies globally. Colchicine can be fatal due to its narrow therapeutic index and potential for interactions. In New Zealand, cases of intentional and unintentional colchicine overdose have been documented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>AIMS<\/jats:title>\n                    <jats:p>To explore patients\u2019 knowledge on the use of gout medicines, and in particular their awareness of the maximum dose of colchicine, the dangers of colchicine overdose, and their opinions on restricting colchicine dispensing. The study also investigates where patients receive gout information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Thirty people with gout presenting to their regular gout clinic in Auckland currently or previously taking colchicine were invited to participate in a 30-min semi-structured interview. Data were analysed using a general inductive thematic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>FINDINGS<\/jats:title>\n                    <jats:p>Overall, participants had a lack of knowledge regarding colchicine and used variable doses during an acute gout attack. Participants were unsure of the maximum dose of colchicine and several took more than prescribed. The prophylactic use of colchicine and allopurinol varied from 3 weeks to 15 years. Mixed views were reported on restricting colchicine supply. Most participants received gout information from their general practitioner (GP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Poor understanding of colchicine contributed to inappropriate use and highlights the need for targeted patient education. Considerable inter-patient variability exists in the use of colchicine for acute gout, suggesting the efficacy of low dose regimens be explored. The length of adjunctive colchicine use, as part of a prophylaxis regimen, needs to be regularly reviewed and tailored to each patient. Further research is required on limiting the amount of colchicine dispensed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1071\/hc15023","type":"journal-article","created":{"date-parts":[[2016,8,14]],"date-time":"2016-08-14T03:29:27Z","timestamp":1471145367000},"page":"140-148","source":"Crossref","is-referenced-by-count":9,"title":["Patient awareness, knowledge and use of colchicine: an exploratory qualitative study in the Counties Manukau region, Auckland, New Zealand"],"prefix":"10.1071","volume":"8","author":[{"given":"Caraliese","family":"Rebello","sequence":"first","affiliation":[{"name":"ASchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maree","family":"Thomson","sequence":"additional","affiliation":[{"name":"ASchool of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Bassett-Clarke","sequence":"additional","affiliation":[{"name":"BTeacher-Practitioner, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland & Counties Manukau Health, Private Bag 92019, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nataly","family":"Martini","sequence":"additional","affiliation":[{"name":"CSenior Lecturer, School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Auckland, New Zealand"},{"name":"DCorrespondence to: Nataly Martini School of Pharmacy, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"67","published-online":{"date-parts":[[2016,6,30]]},"reference":[{"issue":"8","key":"2025111812050112400_R1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/ncprheum0556","article-title":"The changing epidemiology of gout.","volume":"3","author":"Roddy","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"Suppl 1","key":"2025111812050112400_R2","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/ar1907","article-title":"Epidemiology, risk factors, and lifestyle modification for gout.","volume":"8","author":"Saag","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2025111812050112400_R3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/rheumatology\/ker361","article-title":"National prevalence of gout derived from administrative health data in Aotearoa New Zealand.","volume":"51","author":"Winnard","year":"2012","journal-title":"Rheumatology"},{"issue":"2","key":"2025111812050112400_R4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11926-012-0307-x","article-title":"Racial and gender disparities in patients with gout.","volume":"15","author":"Singh","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2025111812050112400_R5","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11926-011-0228-0","article-title":"The patients experience of gout: New insights to optimize management.","volume":"14","author":"Dalbeth","year":"2012","journal-title":"Curr Rheumatol Rep"},{"issue":"11","key":"2025111812050112400_R6","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1136\/annrheumdis-2012-201687","article-title":"Gout: why is this curable disease so seldom cured?","volume":"71","author":"Doherty","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2025111812050112400_R7","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty four-hour outcome of the first multicenter, randomized, double blind, placebo controlled, parallel group, dose comparison colchicine study.","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025111812050112400_R8","unstructured":"Australian Government. Department of Health [internet]. Australia: Pharmaceutical Benefit Schedule, 2013 [cited 23 August 2013]. Available from: www.pbs.gov.au\/medicine\/item\/3410L."},{"key":"2025111812050112400_R9","unstructured":"New Zealand Formulary [internet]. Woods, DJ. Updated September 1, 2012 [cited 19 August 2013]. Available from: www.nzf.org.nz\/nzf_5674.html?searchterm=colchicine."},{"key":"2025111812050112400_R10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","article-title":"Does colchicine work? The results of the first controlled study in acute gout.","volume":"17","author":"Ahern","year":"1987","journal-title":"Aust N Z J Med"},{"issue":"2","key":"2025111812050112400_R11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0736-4679(94)90695-5","article-title":"Colchicine poisoning.","volume":"12","author":"Hood","year":"1994","journal-title":"J Emerg Med"},{"issue":"14","key":"2025111812050112400_R12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.2165\/00002018-200427140-00004","article-title":"Fab antibody fragments.","volume":"27","author":"Flanagan","year":"2004","journal-title":"Drug Saf"},{"issue":"4","key":"2025111812050112400_R13","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/15563657909010599","article-title":"Estimation of colchicine in a poisoned patient by using high performance liquid chromatography.","volume":"14","author":"Jarvie","year":"1979","journal-title":"Clin Toxicol"},{"issue":"1248","key":"2025111812050112400_R14","first-page":"U2402","article-title":"Colchicine overdose: the devil is in the detail.","volume":"120","author":"Jayaprakash","year":"2007","journal-title":"NZ Med J"},{"issue":"7","key":"2025111812050112400_R15","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3109\/15563650.2011.589844","article-title":"Unrecognized fatalities related to colchicine in hospitalized patients.","volume":"49","author":"Mullins","year":"2011","journal-title":"Clin Toxicol"},{"issue":"8","key":"2025111812050112400_R16","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/art.30389","article-title":"Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3a4\/P-glycoprotein inhibitors.","volume":"63","author":"Terkeltaub","year":"2011","journal-title":"Arthritis Rheum"},{"key":"2025111812050112400_R17","unstructured":"U.S. Food and Drug Administration [internet]. Information for Healthcare Professionals: New Safety Information for Colchicine (marketed as Colcrys). [cited 18 August 2003]. Available from: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm174315.htm."},{"issue":"1","key":"2025111812050112400_R18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/rheumatology\/kes211","article-title":"Gout and its comorbidities: implications for therapy.","volume":"52","author":"Stamp","year":"2013","journal-title":"Rheumatology"},{"issue":"5","key":"2025111812050112400_R19","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"2025111812050112400_R20","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin.","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"key":"2025111812050112400_R21","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1345\/aph.1E593","article-title":"Acute myopathy in a patient with concomitant use of pravastatin and colchicine.","volume":"39","author":"Alayli","year":"2005","journal-title":"Ann Pharmacother"},{"issue":"180","key":"2025111812050112400_R22","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/1471-2474-13-180","article-title":"Patients\u2019 knowledge and beliefs concerning gout and its treatment.","volume":"13","author":"Harrold","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"2025111812050112400_R23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/RHU.0b013e318204a8f9","article-title":"The experience and impact of living with gout: a study of men with chronic gout using a qualitative grounded theory approach.","volume":"17","author":"Lindsay","year":"2011","journal-title":"J Clin Rheumatol"},{"key":"2025111812050112400_R24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1742395310378761","article-title":"Patients and providers view gout differently.","volume":"6","author":"Harrold","year":"2010","journal-title":"Chronic Illn"},{"key":"2025111812050112400_R25","unstructured":"Medsafe [internet]. Wellington: New Zealand Medicines and Medical Devices Safety Authority. Colchicine: Lower doses for greater safety; November 2005 [cited 23 August 2013]. Available from: http:\/\/www.medsafe.govt.nz\/profs\/PUArticles\/colchdose.htm."},{"issue":"12","key":"2025111812050112400_R26","first-page":"2430","article-title":"Gout: a very old disease with some new approaches.","volume":"31","author":"Peterson","year":"2013","journal-title":"Australian Pharmacist"},{"issue":"10","key":"2025111812050112400_R27","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis.","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025111812050112400_R28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kep306","article-title":"The modern management of gout.","volume":"49","author":"Rider","year":"2010","journal-title":"Rheumatology"},{"issue":"6","key":"2025111812050112400_R29","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/ncprheum0214","article-title":"Successful treatment with rasburicase of tophaceous gout in a patient allergic to allopurinol.","volume":"2","author":"Richette","year":"2006","journal-title":"Nat Clin Pract Rheumatol"},{"key":"2025111812050112400_R30"},{"issue":"2","key":"2025111812050112400_R31","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/j.2042-7174.2011.00169.x","article-title":"Ethnic differences of medicines-taking in older adults: a cross cultural study in New Zealand.","volume":"20","author":"Bassett-Clarke","year":"2012","journal-title":"Int J Pharm Pract"},{"key":"2025111812050112400_R32","unstructured":"National Prescribing Service [internet]. Colchicine for acute gout: updated information about dosing and drug interactions; 14 May 2010 [cited 5 September 2013]. Available from: http:\/\/www.nps.org.au\/publications\/health-professional\/nps-radar\/2010\/may-2010\/brief-item-colchicine#fnote16."},{"key":"2025111812050112400_R33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/annrheumdis-2013-203325","article-title":"Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative.","volume":"73","author":"Sivera","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"2025111812050112400_R34","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"issue":"7","key":"2025111812050112400_R35","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1001\/archinte.165.7.742","article-title":"Obesity, weight change, hypertension, diuretic use and risk of gout in men: the health professionals follow-up study.","volume":"165","author":"Choi","year":"2005","journal-title":"Arch Intern Med"},{"key":"2025111812050112400_R36","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/431592","article-title":"Fatal interaction between clarithromycin and colchicine in patients with renal insufficiency: A retrospective study.","volume":"41","author":"Hung","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"1265","key":"2025111812050112400_R37","first-page":"U2808","article-title":"Colchicine prescribing and safety monitoring in patients with gout.","volume":"120","author":"Ly","year":"2007","journal-title":"N Z Med J"},{"issue":"2","key":"2025111812050112400_R38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1136\/annrheumdis-2012-202589","article-title":"Low-dose aspirin use and recurrent gout attacks.","volume":"73","author":"Zhang","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"1370","key":"2025111812050112400_R39","first-page":"115","article-title":"Colchicine poisoning: defusing the ticking time bomb.","volume":"126","author":"Gresham","year":"2013","journal-title":"N Z Med J"},{"issue":"3","key":"2025111812050112400_R40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1071\/HC13214","article-title":"M\u0101ori experiences and perceptions of gout and its treatment: a Kaupapa M\u0101ori qualitative study.","volume":"5","author":"Te Karu","year":"2013","journal-title":"J Prim Health Care"},{"issue":"3(7","key":"2025111812050112400_R41","first-page":"41","article-title":"Gout: An alarm bell for diabetes and cardiovascular disease.","author":"Merriman","year":"2011","journal-title":"BPJ"}],"container-title":["The Journal of Primary Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/8\/2\/140\/1326799\/hc15023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/connectsci.au\/hc\/article-pdf\/8\/2\/140\/1326799\/hc15023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T17:05:13Z","timestamp":1763485513000},"score":1,"resource":{"primary":{"URL":"https:\/\/connectsci.au\/hc\/article\/8\/2\/140\/194427\/Patient-awareness-knowledge-and-use-of-colchicine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,30]]},"references-count":41,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,6,30]]},"published-print":{"date-parts":[[2016,6,30]]}},"URL":"https:\/\/doi.org\/10.1071\/hc15023","relation":{},"ISSN":["1172-6156"],"issn-type":[{"type":"electronic","value":"1172-6156"}],"subject":[],"published":{"date-parts":[[2016,6,30]]}}}